Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A defective retroviral vector encoding human interferon-alpha2 can transduce human leukemic cell lines

E Austruy1, C Bagnis, N Carbuccia

  • 1Département de Thérapie Génique, Institut Paoli-Calmettes, Centre Régional de Lutte Contre le Cancer, Marseille, France.

Cancer Gene Therapy
|August 7, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onset of in-plane ferroelectricity in the vanadium dioxide (VO<sub>2</sub>) mott insulator for in-memory computing applications.

Nanotechnology·2026
Same author

Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Bone marrow transplantation·2025
Same author

A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma.

Allergy·2024
Same author

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP).

Bone marrow transplantation·2023

Researchers developed a retroviral vector (LISN) to deliver human interferon-alpha2 (hIFN-alpha2) into leukemia cells. This vector successfully infected and expressed functional hIFN-alpha2, showing potential for gene therapy in leukemia.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Oncology

Background:

  • Retroviral vectors are utilized for gene delivery.
  • Human interferon-alpha2 (hIFN-alpha2) has therapeutic potential in cancer.
  • Developing efficient gene transfer methods for leukemic cells is crucial.

Purpose of the Study:

  • To construct and evaluate a retroviral vector (LISN) encoding hIFN-alpha2 for gene transfer into human hematopoietic and leukemic cell lines.
  • To assess the biological activity and effects of retrovirally delivered hIFN-alpha2 in these cells.

Main Methods:

  • Construction of the LISN retroviral vector encoding hIFN-alpha2.
  • Production of high-titer retroviruses using the GP+envAM12 packaging cell line.
  • Infection of K562, LAMA-84, and TF-1 human leukemic cell lines.

Related Experiment Videos

  • Analysis of hIFN-alpha2 expression and secretion via Northern blot, FACS, and ELISA.
  • Assessment of biological activity, including cell growth inhibition, antigen modulation, and protein down-modulation.

    • Main Results:

    • LISN retrovirus was produced at high titers and successfully infected human leukemic cell lines.
    • Infected cells expressed and secreted biologically active hIFN-alpha2.
    • Retrovirally delivered hIFN-alpha2 demonstrated anti-leukemic effects, including growth inhibition and modulation of specific cellular markers and proteins (e.g., BCR-ABL).
    • hIFN-alpha2 expression did not significantly inhibit retroviral particle production or cell infection.

    Conclusions:

    • Gene transfer into human leukemic cell lines using the LISN retroviral vector encoding hIFN-alpha2 is feasible.
    • The delivered hIFN-alpha2 exhibits expected biological activity, suggesting therapeutic potential.
    • This system provides a valuable model for investigating autocrine hIFN-alpha2 effects in normal and leukemic cells and hematopoietic progenitors.